Comparison for the Effect of Neuromuscular Blocking Agents Versus Sedation Alone on Severe ARDS Patients Due to COVID-19

Assiut University

Status: Completed

Conditions: Sedation Complication; COVID-19 Acute Respiratory Distress Syndrome; ICU Acquired Weakness

Treatments: Drug: muscle relaxation

Study type: Interventional

Funder types: Other

Identifiers

NCT04922814

Covid-19 ICU

Details and patient eligibility

About

Many questions about management of COVID-19 are still not answered. So, we recruit this study aiming to evaluate improvement of oxygenation in COVID-19 patients with severe ARDS, to improve morbidity and mortality of ICU covid patients, to participate in understanding of real hidden pathophysiology of COVID-19.

Enrollment: 40 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Severe ARDS: PaO2/FiO2 <200, resistant hypoxemia and tachypnoea (RR > 40 breath/minute)
• Not relieved by high frequency nasal canula or CPAP.
• Need for invasive mechanical ventilation (uncooperative)

Exclusion criteria

• Patient relatives' refusal
• Not mechanically ventilated.
• Combination of female, corticosteroids administration and vecuronium muscle relaxant.
• Neuromuscular diseases (especially demyelinating diseases).

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

40 participants in 2 patient groups

Control group(group A)

No Intervention group

Description:

Only sedation for mechanically ventilated COVID patients

Muscle relaxant group(group B)

Experimental group

Description:

They will receive muscle relaxation treatment for at least 48 hours. Cisatracurium will be given. Short term infusions up to 24 hours will be given in a dose rate of 2-3 mic/Kg/min followed by intervallic shots of 2-5 mg.

Treatment:

Drug: muscle relaxation